Recently, Merck Corporation (MSD) announced that the US FDA approved its heavy immunotherapy Keytruda (pembrolizumab) for the treatment of patients with advanced cervical cancer, which is the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer.
Keytruda is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, inhibiting tumors through the PD-1 pathway-mediated immune response, including Anti-tumor immune response. In a tumor model of syngeneic mice, Keytruda blocks PD-1 activity and slows tumor growth.
Previously, Keytruda has been approved for the treatment of cancer such as melanoma, non-small cell lung cancer, classic Hodgkin's lymphoma, head and neck squamous cell carcinoma, and urothelial carcinoma. In a clinical trial called KEYNOTE-158, Keytruda's therapeutic effect in cervical cancer has also been validated.
KEYNOTE-158 II This is a global, open, non-randomized, multi-linear, multi-center clinical study with a primary end point of objective response rate (ORR). The clinical study enrolled 98 recurrent or metastatic cervical tracts. Cancer patients were treated with Keytruda (200 mg) every three weeks. In 77 (79%) patients with PD-L1 (comprehensive positive score of not less than 1), Keytruda achieved a general response rate of 14.3% (95% CI: 7.4% – 24.1%). The complete response rate was 2.6%. In patients with effective treatment, the median remission time has not been reached, and 91% of patients have a remission time of more than half a year. Keytruda did not show an effect in patients with tumor PD-L1 expression levels below 1. Based on these data, the US FDA approved its marketing to treat patients with advanced cervical cancer who have progressed after chemotherapy and who have developed PD-L1.
Machine Tool Calibration,Machine Tool Swivel Check,Angle Pendulum Tester,Machine Tool Calibrator
Automated Precision Inc. , https://www.apiasean.com